Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
CD163 Antibody (10D6), Novus Biologicals™
Mouse Monoclonal Antibody has been used in 12 publications
Supplier: Novus Biologicals NB11059935SS
Description
CD163 Monoclonal specifically detects CD163 in Human samples. It is validated for Immunohistochemistry, Immunocytochemistry/Immunofluorescence, Immunohistochemistry-Paraffin.Specifications
CD163 | |
Monoclonal | |
Unconjugated | |
Tissue culture supernatant with 0.05% Sodium Azide | |
CD163 antigenscavenger receptor cysteine-rich type 1 protein M130, CD163 molecule, Hemoglobin scavenger receptor, M130, M130macrophage-associated antigen, MM130 | |
Mouse | |
Tissue culture supernatant | |
RUO | |
9332 | |
Human | |
Supernatant |
Immunohistochemistry, Immunocytochemistry, Immunofluorescence, Immunohistochemistry (Paraffin) | |
10D6 | |
Immunohistochemistry 1:10-1:500, Immunocytochemistry/Immunofluorescence 1:10-1:500, Immunohistochemistry-Paraffin | |
Q86VB7 | |
CD163 | |
Human CD163 antigen. | |
0.1 mL | |
Primary | |
This CD163 molecule is a type I membrane protein also known as M130 antigen, Ber-Mac3, Ki-M8 or SM4. CD163 protein is restricted in its expression to the monocytic/macrophage lineage. It is reported to be present on all circulating monocytes and most tissue macrophages except those found in the mantle zone and germinal centers of lymphoid follicles, interdigitating reticulum cells, and Langerhans cells. Multinucleated cells within inflammatory lesions are reported not to express CD163 protein. The protein is upregulated by glucocorticoids and is downregulated by immunosuppressant cyclosporin A and phorbol esters. | |
Store at 4C. Do not freeze. | |
IgG1 |
Provide Content Correction
We continue to work to improve your shopping experience and your feedback regarding this content is very important to us. Please use the form below to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?
Provide Content Correction